TP53 and renal carcinoma: After benchmarking RENOIR over commonly used datasets and reporting its successful application in recent studies focusing on the identification of classifiers for SET2D mutation status in renal cancer and TP53 mutation status in cancer cell lines and samples, we employed our software to address a major pharmacological challenge: the prediction of drug efficacy26.